FRM
ALLO icon

Fox Run Management’s Allogene Therapeutics ALLO Stock Holding History

Fox Run Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,215
Closed -$164K – 596
2022
Q3 		$164K Buy
+15,215
New +$207K 0.06% 508
2022
Q2 		– Sell
-16,712
Closed -$152K – 506
2022
Q1 		$152K Buy
+16,712
New +$174K 0.08% 433

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fox Run Management's ALLO Position: Q4 2022 in Review

Fox Run Management sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 15,215 shares — an estimated $164K sold.

Fox Run Management first reported a position in ALLO in Q1 2022 and held it in 2 quarters. The position peaked at $164K in Q3 2022. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Fox Run Management reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Fox Run Management sold 15,215 Allogene Therapeutics shares in Q4 2022, an estimated $164K.
  • Fox Run Management first reported a position in Allogene Therapeutics in Q1 2022 and held it in 2 quarters.
  • Fox Run Management's Allogene Therapeutics position peaked at $164K in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Fox Run Management's 13F filing for Q4 2022, filed 7 Feb 2023.